EA201101194A1 - Применение розувастатин лактолов в качестве лекарственных препаратов - Google Patents

Применение розувастатин лактолов в качестве лекарственных препаратов

Info

Publication number
EA201101194A1
EA201101194A1 EA201101194A EA201101194A EA201101194A1 EA 201101194 A1 EA201101194 A1 EA 201101194A1 EA 201101194 A EA201101194 A EA 201101194A EA 201101194 A EA201101194 A EA 201101194A EA 201101194 A1 EA201101194 A1 EA 201101194A1
Authority
EA
Eurasian Patent Office
Prior art keywords
application
medicine preparation
rosuvastatin
rosuvastatin lactol
lactol
Prior art date
Application number
EA201101194A
Other languages
English (en)
Other versions
EA022783B1 (ru
Inventor
Дерек Линдсэй
Питер Джексон
Original Assignee
Редкс Фарма Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Редкс Фарма Лимитед filed Critical Редкс Фарма Лимитед
Publication of EA201101194A1 publication Critical patent/EA201101194A1/ru
Publication of EA022783B1 publication Critical patent/EA022783B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Abstract

Данное изобретение относится к открытию новых аналогов розувастатина. Более конкретно, изобретение относится к новым аналогам розувастатина, которые применяют в лечении болезненных состояний, которые поддаются лечению путем ингибирования HMG-CoA редуктазы.
EA201101194A 2009-03-10 2010-03-10 ПРИМЕНЕНИЕ АНАЛОГОВ РОЗУВАСТАТИНА ДЛЯ ЛЕЧЕНИЯ БОЛЕЗНЕННЫХ СОСТОЯНИЙ, КОТОРЫЕ ПОДДАЮТСЯ ЛЕЧЕНИЮ ПУТЕМ ИНГИБИРОВАНИЯ HMG-CoA РЕДУКТАЗЫ EA022783B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0904100.5A GB0904100D0 (en) 2009-03-10 2009-03-10 Use of rosuvastatin lactols as medicaments
PCT/GB2010/050409 WO2010103320A1 (en) 2009-03-10 2010-03-10 Use of rosuvastatin lactols as medicaments

Publications (2)

Publication Number Publication Date
EA201101194A1 true EA201101194A1 (ru) 2012-04-30
EA022783B1 EA022783B1 (ru) 2016-03-31

Family

ID=40600801

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201101194A EA022783B1 (ru) 2009-03-10 2010-03-10 ПРИМЕНЕНИЕ АНАЛОГОВ РОЗУВАСТАТИНА ДЛЯ ЛЕЧЕНИЯ БОЛЕЗНЕННЫХ СОСТОЯНИЙ, КОТОРЫЕ ПОДДАЮТСЯ ЛЕЧЕНИЮ ПУТЕМ ИНГИБИРОВАНИЯ HMG-CoA РЕДУКТАЗЫ

Country Status (19)

Country Link
US (2) US20120004408A1 (ru)
EP (1) EP2405972B1 (ru)
JP (1) JP5765739B2 (ru)
KR (1) KR20110128194A (ru)
CN (1) CN102387837B (ru)
AU (1) AU2010222658B2 (ru)
BR (1) BRPI1009442A2 (ru)
CA (1) CA2754825A1 (ru)
DK (1) DK2405972T3 (ru)
EA (1) EA022783B1 (ru)
ES (1) ES2409406T3 (ru)
GB (1) GB0904100D0 (ru)
IL (1) IL215039A (ru)
MX (1) MX2011009456A (ru)
NZ (1) NZ595116A (ru)
PL (1) PL2405972T3 (ru)
PT (1) PT2405972E (ru)
WO (1) WO2010103320A1 (ru)
ZA (1) ZA201107053B (ru)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0904104D0 (en) 2009-03-10 2009-04-22 Bradford Pharma Ltd Atorvastatin and rosuvastatin derivatives
GB0904102D0 (en) * 2009-03-10 2009-04-22 Bradford Pharma Ltd Use of atorvastatin lactols as medicaments
GB0904100D0 (en) 2009-03-10 2009-04-22 Bradford Pharma Ltd Use of rosuvastatin lactols as medicaments
WO2014045294A1 (en) * 2012-09-20 2014-03-27 Inogent Laboratories Private Limited A novel process for the preparation of rosuvastatin calcium using novel intermediates
US9174962B2 (en) 2013-10-17 2015-11-03 Dow Agrosciences Llc Processes for the preparation of pesticidal compounds
US9102655B2 (en) 2013-10-17 2015-08-11 Dow Agrosciences Llc Processes for the preparation of pesticidal compounds
KR20160072154A (ko) 2013-10-17 2016-06-22 다우 아그로사이언시즈 엘엘씨 살충성 화합물의 제조 방법
MX2016004941A (es) 2013-10-17 2016-06-28 Dow Agrosciences Llc Proceso para la preparacion de compuestos plaguicidas.
US10449210B2 (en) 2014-02-13 2019-10-22 Ligand Pharmaceuticals Inc. Prodrug compounds and their uses
CN104293849A (zh) * 2014-06-10 2015-01-21 常州金隆生物医药有限公司 一种瑞舒伐他汀钙的制备方法
EP3174856A4 (en) 2014-07-31 2018-01-10 Dow AgroSciences LLC Process for the preparation of 3-(3-chloro-1h-pyrazol-1-yl)pyridine
US10467988B2 (en) * 2015-02-25 2019-11-05 Rockwell Automation Asia Pacific Business Center Pte. Ltd. Amalgamated alphanumeric character display system and method
PL124682U1 (pl) * 2015-12-16 2017-06-19 Ewa Edyta Bujak Zestaw rehabilitacyjny układanki sensorycznej, zwłaszcza dla dzieci z zaburzeniami psychomotorycznymi
EP3737676B1 (en) * 2018-01-09 2024-03-06 Ligand Pharmaceuticals, Inc. Acetal compounds and therapeutic uses thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4681893A (en) 1986-05-30 1987-07-21 Warner-Lambert Company Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis
ATE132496T1 (de) * 1987-07-10 1996-01-15 Hoechst Ag 3-desmethyl-mevalonsäurederivate, verfahren zu ihrer herstellung, pharmazeutische präparate auf basis dieser verbindungen, ihre verwendung sowie zwischenprodukte
FI94339C (fi) 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
JP2648897B2 (ja) 1991-07-01 1997-09-03 塩野義製薬株式会社 ピリミジン誘導体
BRPI0412786A (pt) * 2003-07-25 2006-09-26 Avecia Pharmaceuticals Ltd processo para a preparação de um composto, e, composto
GB0406757D0 (en) * 2004-03-26 2004-04-28 Avecia Ltd Process and compounds
DE102005022284A1 (de) * 2005-05-13 2006-11-23 Ratiopharm Gmbh Verfahren zur Herstellung von Statinen
EP1834944A1 (en) * 2006-03-17 2007-09-19 Ratiopharm GmbH Process for preparing C7 intermediates and their use in the preparation on N-substituted pyrrole derivatives
GB0904102D0 (en) 2009-03-10 2009-04-22 Bradford Pharma Ltd Use of atorvastatin lactols as medicaments
GB0904104D0 (en) 2009-03-10 2009-04-22 Bradford Pharma Ltd Atorvastatin and rosuvastatin derivatives
GB0904100D0 (en) 2009-03-10 2009-04-22 Bradford Pharma Ltd Use of rosuvastatin lactols as medicaments

Also Published As

Publication number Publication date
EA022783B1 (ru) 2016-03-31
IL215039A0 (en) 2011-11-30
KR20110128194A (ko) 2011-11-28
DK2405972T3 (da) 2013-06-10
JP2012520281A (ja) 2012-09-06
CN102387837B (zh) 2015-11-25
US20140018381A1 (en) 2014-01-16
EP2405972A1 (en) 2012-01-18
MX2011009456A (es) 2012-04-10
NZ595116A (en) 2013-02-22
US9102656B2 (en) 2015-08-11
GB0904100D0 (en) 2009-04-22
PT2405972E (pt) 2013-06-05
BRPI1009442A2 (pt) 2016-03-01
AU2010222658A1 (en) 2011-09-29
EP2405972B1 (en) 2013-03-06
CN102387837A (zh) 2012-03-21
US20120004408A1 (en) 2012-01-05
WO2010103320A1 (en) 2010-09-16
CA2754825A1 (en) 2010-09-16
IL215039A (en) 2014-12-31
AU2010222658B2 (en) 2014-10-02
JP5765739B2 (ja) 2015-08-19
ZA201107053B (en) 2014-03-26
PL2405972T3 (pl) 2013-10-31
ES2409406T3 (es) 2013-06-26

Similar Documents

Publication Publication Date Title
EA201101194A1 (ru) Применение розувастатин лактолов в качестве лекарственных препаратов
EA201190259A1 (ru) Противовирусные соединения
UY33735A (es) Compuestos antivirales
TN2012000578A1 (en) Tetrahydro-pyrido-pyrimidine derivatives
EA201491412A1 (ru) Соединения для лечения спинальной мышечной атрофии
EA201390060A1 (ru) Аннелированные пиримидины и триазины и их применение для лечения и/или профилактики сердечно-сосудистых заболеваний
EA201190217A1 (ru) Замещенные 2-ацетамидо-5-арил-1,2,4-триазолоны и их применение
EA201491766A1 (ru) Соединения для лечения спинальной мышечной атрофии
EA201101620A1 (ru) Ингибиторы репликации вируса иммунодефицита человека
WO2013163190A8 (en) Dna-pk inhibitors
EA201200473A1 (ru) Замещенные (гетероарилметил)тиогидантоины
EA201201374A1 (ru) Лечение атаксии-телеангиэктазии
EA201001847A1 (ru) Соединения и композиции, применяемые для лечения малярии
EA201270257A1 (ru) Производные n1-сульфонил-5-фторпиримидинона
EA201200551A1 (ru) Фармацевтическая композиция, фармацевтическая дозированная форма, способы их получения и применения для лечения
MX2012007098A (es) Derivados fenolicos y su uso farmaceutico o cosmetico.
MX2012007161A (es) Derivados fenolicos y su uso farmaceutico o cosmetico.
EA201490423A1 (ru) СПОСОБЫ И КОМПОЗИЦИИ, ОТНОСЯЩИЕСЯ К p62, ДЛЯ ЛЕЧЕНИЯ И ПРОФИЛАКТИКИ РАКА
UA86731C2 (ru) Делимая галеновая форма модифицированного высвобождения активного ингредиента
EA201200098A1 (ru) Конденсированные имидазолы и содержащие их композиции, предназначенные для лечения паразитарных заболеваний, таких как, например, малярия
EA201270256A1 (ru) Производные т1-замещенного 5-фтор-2-оксопиримидинон-1 (2h) -карбоксамида
EA201300034A1 (ru) Фармацевтические композиции, содержащие иматиниб или его фармацевтически приемлемую соль, и способы их получения
UA106889C2 (uk) Похідні n1-ацил-5-фторпіримідинону
EA201071367A1 (ru) Соли соединений ингибиторов вич
UA107455C2 (ru) Производные индола как противораковые агенты

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU